Optimum Investment Advisors Sells 300 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Optimum Investment Advisors lessened its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 15.9% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 1,583 shares of the company’s stock after selling 300 shares during the period. Optimum Investment Advisors’ holdings in GE HealthCare Technologies were worth $144,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. CHURCHILL MANAGEMENT Corp purchased a new position in shares of GE HealthCare Technologies during the first quarter valued at approximately $8,296,000. Wynn Capital LLC raised its stake in shares of GE HealthCare Technologies by 4.1% during the 1st quarter. Wynn Capital LLC now owns 3,125 shares of the company’s stock valued at $284,000 after purchasing an additional 122 shares during the period. Park Avenue Securities LLC bought a new stake in shares of GE HealthCare Technologies during the 1st quarter valued at $227,000. American National Bank raised its stake in shares of GE HealthCare Technologies by 102.7% during the 1st quarter. American National Bank now owns 1,520 shares of the company’s stock valued at $138,000 after purchasing an additional 770 shares during the period. Finally, Banque Cantonale Vaudoise grew its position in GE HealthCare Technologies by 49.1% during the first quarter. Banque Cantonale Vaudoise now owns 14,627 shares of the company’s stock worth $1,331,000 after buying an additional 4,817 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Buying and Selling at GE HealthCare Technologies

In other GE HealthCare Technologies news, CTO Taha Kass-Hout sold 3,300 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $78.70, for a total transaction of $259,710.00. Following the sale, the chief technology officer now directly owns 67,300 shares of the company’s stock, valued at $5,296,510. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other GE HealthCare Technologies news, CTO Taha Kass-Hout sold 3,300 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $78.70, for a total transaction of $259,710.00. Following the sale, the chief technology officer now directly owns 67,300 shares of the company’s stock, valued at $5,296,510. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Jan Makela sold 20,227 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $81.57, for a total value of $1,649,916.39. Following the sale, the chief executive officer now directly owns 63,348 shares in the company, valued at $5,167,296.36. The disclosure for this sale can be found here. Insiders have sold a total of 90,482 shares of company stock valued at $7,369,137 over the last ninety days. 0.27% of the stock is currently owned by company insiders.

GE HealthCare Technologies Price Performance

Shares of GE HealthCare Technologies stock opened at $79.17 on Friday. GE HealthCare Technologies Inc. has a one year low of $62.35 and a one year high of $94.50. The stock’s fifty day moving average is $80.53 and its 200 day moving average is $81.48. The stock has a market cap of $36.14 billion, a P/E ratio of 23.15, a P/E/G ratio of 2.86 and a beta of 1.22. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.83 and a current ratio of 1.06.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $0.90 EPS for the quarter, meeting analysts’ consensus estimates of $0.90. The business had revenue of $4.65 billion for the quarter, compared to analysts’ expectations of $4.80 billion. GE HealthCare Technologies had a return on equity of 25.32% and a net margin of 8.05%. The business’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period last year, the firm earned $0.85 earnings per share. Sell-side analysts anticipate that GE HealthCare Technologies Inc. will post 4.27 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. The Goldman Sachs Group began coverage on GE HealthCare Technologies in a research report on Thursday, May 30th. They set a “neutral” rating and a $87.00 target price for the company. Citigroup upped their price target on GE HealthCare Technologies from $88.00 to $103.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Bank of America cut their price target on GE HealthCare Technologies from $94.00 to $86.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 1st. Mizuho cut their target price on GE HealthCare Technologies from $110.00 to $105.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Finally, Evercore ISI increased their target price on GE HealthCare Technologies from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $94.09.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.